RENB-HB-01: HBV Gene Therapy

RENB-HB-01 is in early pre-clinical phase as we explore various approaches for gene therapy design elements. If those explorations are successful, it is possible we could begin the regulatory process at the earliest in the first half of 2024. However, our highest priority for investment is the oncology platform, beginning with pancreatic cancer.